Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.
ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.
Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.
In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.